Effective integration of medical and pharmacy claims to better protect patient safety - A long road yet to travel

Journal of Managed Care Pharmacy

Volumn 13, Issue 5, 2007, Pages 429-430

  Curtiss, Frederic R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; GATIFLOXACIN; MOXIFLOXACIN; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TROVAFLOXACIN;

ASTHMA; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG LABELING; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH INSURANCE; HEPATITIS; HUMAN; LIVER FAILURE; LIVER TOXICITY; MANAGED CARE ORGANIZATION; NONHUMAN; OFF LABEL DRUG USE; PATIENT SAFETY; PRESCRIPTION; RESPIRATORY TRACT INFECTION; RISK BENEFIT ANALYSIS; SINUSITIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

EID: 34547448123     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.5.429     Document Type: Editorial

References (14)

1. Clay KD, Hanson JS, Pope SD, Rissmiller RW Purdum PP, Banks PM. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med. 2006;144:415-20.
2. Dooren JC. Sanofi antibiotic may be tied to liver problems, doctors say. Wall Street Journal. January 21-22, 2006:A6.
3. Mathews AW. FDA panel urges prominent warning label for antibiotic. Wall Street Journal. May 19, 2006:B1, B2.
4. Community practice. Top 200 brand-name drugs by retail dollars in 2005. Drug Top. March 6, 2006:26.
5. Ross DB.The FDA and the case of Ketek (commentary). N Engl J Med. 2007;356:1601-04.
6. Letter from Senator Charles Grassley to FDA Commissioner Andrew C von Eschenbach, December 13, 2006. Available at: http://finance.senate.gov/ press/Gpress/2005/Prg121306a.pdf. Accessed May 30, 2007.
7. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Telithromycin (marketed as Ketek) information. February 12, 2007. Available at: http://www.fda.gov/cder/drug/infopage/telithromycin/ default.htm. Accessed May 30, 2007.
8. Gleason PP, Walters C, Heaton AH, Schafer JA. Telithromycin: the perils of hasty adoption and persistence of off-label prescribing. J Manag Care Pharm. 2007;13(5):420-25. Available at: http://www.amcp.org/ data/jmcp/420-25.pdf.
9. Johnston SL, Blasi F, Black PN, Martin RJ, Farrell DJ, Nierman RB, for the TELICAST Investigators. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med. 2007;354:1589-1600.
10. Little FF. Treating acute asthma with antibiotics - not quite yet, N Engl J Med. 2007;354:1632-34.
11. Telithromycin (Ketek) for respiratory infections. Med Letter. August 16, 2004;46:66-68.
12. Mintzes B. Pharmaceutical promotion and prevention of antibiotic resistance [abstract]. October 2005. Available at: http://www.pasteur.fr/ applications/euroconf/antiinmfectionstherapies/7_Mintzes_abstract_pdf Accessed June 2, 2007.
13. Peabody JW, Luck J, Jain S, Bertenthal D, Glassman P. Assessing the accuracy of administrative data in health information systems. Med Care. 2004;42(11):1066-72.
14. Chadha NK, Chadha R. 10-minute consultation: sinusitis. BMJ. 2007;334: 1165. [doi:10.1136/bmj.39161.557211.47].